Clinical Gastroenterology and Hepatology
Volume 5, Issue 11 , Pages 1313-1315 , November 2007

Transplantation Trends in Primary Biliary Cirrhosis

  • Jarone Lee

      Affiliations

    • Department of Medicine, Division of Liver Diseases/Transplant Institute, Mount Sinai Medical Center, New York, New York
    • ,
  • Adam Belanger

      Affiliations

    • Department of Medicine, Division of Liver Diseases/Transplant Institute, Mount Sinai Medical Center, New York, New York
    • ,
  • John T. Doucette

      Affiliations

    • Department of Community and Preventive Medicine, Division of Biostatistics and Data Management, Mount Sinai Medical Center, New York, New York
    • ,
  • Carmen Stanca

      Affiliations

    • Department of Medicine, Division of Liver Diseases/Transplant Institute, Mount Sinai Medical Center, New York, New York
    • ,
  • Scott Friedman

      Affiliations

    • Department of Medicine, Division of Liver Diseases/Transplant Institute, Mount Sinai Medical Center, New York, New York
    • ,
  • Nancy Bach

      Affiliations

    • Department of Medicine, Division of Liver Diseases/Transplant Institute, Mount Sinai Medical Center, New York, New York
    • Corresponding Author InformationAddress requests for reprints to: Nancy Bach, MD, Division of Liver Diseases/Transplant Institute, Mount Sinai Hospital, 5 East 98th Street, New York, New York 10029. fax: (212) 289-7738.

References 

  1. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005;353:1261–1273
  2. Roberts MS, Angus DC, Bryce CL, et al. Survival after liver transplantation in the United States: a disease specific analysis of the UNOS database. Liver Transpl. 2004;10:886–897
  3. Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 2005;128:297–303
  4. ter Borg PC, Schalm SW, Hansen BE, et al. Dutch PBC Study Group Prognosis of ursodeoxycholic acid treated patients with primary biliary cirrhosis: results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol. 2006;101:2044–2050
  5. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715–720
  6. Lindor KD. Ursodiol for primary sclerosing cholangitis. N Engl J Med. 1997;336:691–695
  7. LaRusso NF, Shneider BL, Black D, et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology. 2006;44:746–764
  8. Sood S, Gow PJ, Christie JM, et al. Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations. Gastroenterology. 2004;127:470
  9. Kim WR, Lindor KD, Locke GR, et al. Epidemiology and natural history of primary biliary cirrhosis in a U.S. community. Gastroenterology. 2000;119:1631–1636
  10. James OF, Bhopal R, Howel D, et al. Primary biliary cirrhosis once rare, now common in the United Kingdom?. Hepatology. 1999;30:390
  11. Heathcote JE. Management of primary biliary cirrhosis. Hepatology. 2000;31:1005–1013
  12. LaRusso NF, Shneider BL, Black D, et al. Primary sclerosing cholangitis—summary of a workshop. Hepatology. 2006;44:746–764
  13. Vierling JM, Teperman LW. Introduction to hepatitis B transplantation. Semin Liver Dis. 2000;20(Suppl 1):1–2

PII: S1542-3565(07)00718-5

doi: 10.1016/j.cgh.2007.07.015

Clinical Gastroenterology and Hepatology
Volume 5, Issue 11 , Pages 1313-1315 , November 2007